Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 159
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology.
Times cited: 105
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
The Lancet. Oncology.
Times cited: 555